Neurochem Inc. About
Neurochem Inc. Neurochem's strategic plan focuses on the further
development of a strong, steadily expanding pipeline of product candidates addressing
vital unmet medical needs. These products focus primarily on neurological diseases.
With promising drug candidates currently in clinical trials for AA
Amyloidosis, Alzheimer's
disease, and hemorrhagic
stroke due to cerebral amyloid angiopathy, and with expanding drug development
programs for other research projects, AA Amyloidosis: Fibrillex™ Alzhemed™
--Alzheimer's Disease --inhibit the amyloid cascade : Level
of Action: --prevent and stop the formation and deposition of amyloid fibrils
in the brain by binding to soluble Aß prior to fibril formation; --to favor
the clearance of soluble Aß from the brain, lowering the risk of fibril formation
--to inhibit the inflammatory response associated with amyloid build-up
in Alzheimer's disease.
Cerebril™
--Hemorrhagic stroke due to cerebral amyloid angiopathy:
More Info on Neurochem Corp